ROCK2抑制剂Belumosudil治疗慢性移植物抗宿主病的IIa期研究
这项IIa期开放标签剂量探索研究纳入54例既往接受1-3线治疗的慢性GVHD患者,评估ROCK2抑制剂belumosudil的疗效。结果显示200mg每日一次、200mg每日两次和400mg每日一次组的总体缓解率分别为65%、69%和62%,中位缓解持续时间35周,2年总生存率82%,且耐受性良好。
要点
- Belumosudil在经治慢性GVHD中总体缓解率达62%-69%,中位缓解持续时间35周。
- 缓解伴随生活质量改善和糖皮质激素减量,19%患者停用糖皮质激素。
- 2年总生存率82%,6个月和12个月无失败生存率分别为76%和47%。
核心结论
- Belumosudil治疗经治慢性GVHD获得高总体缓解率和总生存率,并改善生活质量、减少糖皮质激素用量且毒性有限。
研究设计与样本
- IIa期、开放标签、剂量探索研究,纳入54例既往接受1-3线治疗的慢性GVHD患者。
主要发现
- Belumosudil 200mg每日一次、200mg每日两次和400mg每日一次组的总体缓解率分别为65%(95%CI 38%-86%)、69%(95%CI 41%-89%)和62%(95%CI 38%-82%)。
- 中位缓解持续时间为35周。
- 6个月和12个月无失败生存率分别为76%(95%CI 62%-85%)和47%(95%CI 33%-60%)。
- 2年总生存率为82%(95%CI 69%-90%)。
- 19%的患者停用糖皮质激素。
关键数值与推荐
- 从慢性GVHD诊断至入组的中位时间为20个月。
临床怎么用
- Belumosudil可能成为治疗难治性慢性GVHD的有效选择,且耐受性良好、血细胞减少发生率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The rho-associated coiled-coil-containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T cells balance and controls profibrotic pathways. Selective ROCK2 inhibition with belumosudil (KD025) may offer a novel approach to the management of chronic graft-versus-host disease (cGVHD). PATIENTS AND METHODS: A phase IIa, open-label, dose-finding study of belumosudil enrolled 54 patients with cGVHD who had received one to three prior lines of therapy (LOTs). The primary end point was overall response rate (ORR). RESULTS: The median time from cGVHD diagnosis to enrollment was 20 months. Seventy-eight percent of patients had severe cGVHD, 50% had ≥ 4 organs involved, 73% had cGVHD refractory to their last LOT, and 50% had received ≥ 3 prior LOTs. With an overall median follow-up of 29 months, the ORR (95% CI) with belumosudil 200 mg once daily, 200 mg twice daily, and 400 mg once daily was 65% (38% to 86%), 69% (41% to 89%), and 62% (38% to 82%), respectively. Responses were clinically meaningful, with a median duration of response of 35 weeks, and were associated with quality-of-life improvements and corticosteroid (CS) dose reductions. CS treatment was discontinued in 19% of patients. The failure-free survival rate was 76% (62% to 85%) and 47% (33% to 60%) at 6 and 12 months, respectively. The 2-year overall survival rate was 82% (69% to 90%). Belumosudil was well-tolerated, with low rates of cytopenia. There were no unexpected adverse events and no apparent increased risk of infection, including cytomegalovirus infection and reactivation. CONCLUSION: Belumosudil treatment resulted in a high ORR and overall survival rate and demonstrated quality-of-life improvements, CS dose reductions, and limited toxicity. Data from the study indicated that belumosudil may prove to be an effective therapy for patients with treatment-refractory cGVHD.
引用
- Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021. PMID: 33877856. doi:10.1200/JCO.20.02754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。